PT  - JOURNAL ARTICLE
AU  - Kyle E. Watters
AU  - Haridha Shivram
AU  - Christof Fellmann
AU  - Rachel J. Lew
AU  - Blake McMahon
AU  - Jennifer A. Doudna
TI  - Potent CRISPR-Cas9 inhibitors from <em>Staphylococcus</em> genomes
AID  - 10.1101/799403
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 799403
4099  - http://biorxiv.org/content/early/2019/10/09/799403.short
4100  - http://biorxiv.org/content/early/2019/10/09/799403.full
AB  - Anti-CRISPRs (Acrs) are small proteins that inhibit the RNA-guided DNA targeting activity of CRISPR-Cas enzymes. Encoded by bacteriophage and phage-derived bacterial genes, Acrs prevent CRISPR-mediated inhibition of phage infection and can also block CRISPR-Cas-mediated genome editing in eukaryotic cells. To identify Acrs capable of inhibiting Staphylococcus aureus Cas9 (SauCas9), an alternative to the most commonly used genome editing protein Streptococcus pyogenes Cas9 (SpyCas9), we used both self-targeting CRISPR screening and guilt-by-association genomic search strategies. Here we describe three new potent inhibitors of SauCas9 that we name AcrIIA13, AcrIIA14 and AcrIIA15. These inhibitors share a conserved N-terminal sequence that is dispensable for anti-CRISPR function, and have divergent C-termini that are required in each case for selective inhibition of SauCas9-catalyzed DNA cleavage. In human cells, we observe robust and specific inhibition of SauCas9-induced genome editing by AcrIIA13 and moderate inhibition by AcrIIA14 and AcrIIA15. We also find that the conserved N-terminal domain of AcrIIA13-15 binds to an inverted repeat sequence in the promoter of these Acr genes, consistent with its predicted helix-turn-helix DNA binding structure. These data demonstrate an effective strategy for Acr discovery and establish AcrIIA13-15 as unique bifunctional inhibitors of SauCas9.